Navigation Links
Compendia Bioscience Announces Collaboration with MDS Pharma Services to Deliver Novel Solution for Oncology Drug Development
Date:4/28/2009

ANN ARBOR, Mich., April 28 /PRNewswire/ -- Compendia Bioscience today announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor(SM) -- a novel solution for improved cancer drug development. OncoPredictor(SM) combines MDS Pharma Services OncoPanel(TM) with Compendia Bioscience's Oncomine(TM) for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO )

MDS Pharma Services OncoPanel(TM) service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations. Compendia's Oncomine(TM), a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types. Through this collaboration, the OncoPredictor(SM) system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology.

"Based on our experience working with 15 of the top 20 companies pursuing the development of cancer treatments, we believe this integrated solution could revolutionize cancer genomics for drug development," said Compendia CEO and Co-founder Dan Rhodes, Ph.D. "All of our customers are keenly interested in identifying which patients are mostly likely to respond to their new drugs. OncoPredictor(SM) provides the right experimental scale, in terms of cell line data and reference patient data, to deliver the answers our customers are seeking."

MDS Pharma Services is the only contract research organization with firsthand experience of delivering high quality cellular data on such a large scale using the exact growth and culture conditions from which the genomic data in Oncomine(TM) was generated.

"MDS Pharma Services clearly provides unique experience and capabilities," continued Rhodes. "We do not believe we could have identified a better partner to co-develop this solution."

The solution will be delivered as a stand-alone, end-to-end service and will not require a license to any of Compendia's Oncomine offerings.

"MDS Pharma Services is pleased to collaborate with Compendia Bioscience to develop OncoPredictor(SM), which will help clients developing cancer treatments to do so more effectively and quickly," said David Spaight, MDS Pharma Services president. "Compendia Bioscience is a leader in the field of cancer genomics and Oncomine(TM) has become a standard platform in the industry. We believe our joint solution - OncoPredictor(SM) - can also become an industry standard in oncology drug development at a cost affordable for both large and smaller companies"

About Compendia Bioscience's Oncomine(TM)

Oncomine(TM) combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine(TM) facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About MDS Pharma Services OncoPanel(TM)

MDS Pharma Services' OncoPanel(TM) offers high-throughput cellular drug profiling, relying on deep experience in cell culture and high content imaging to systematically screen compounds across hundreds of cancer cell lines simultaneously.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services.

MDS Pharma Services Pharmacology/DMPK division, offers biochemical, cellular/functional, ADME/DMPK and in vivo assays for use in identifying lead compounds, profiling for selectivity, determining the potential for adverse events, evaluating efficacy and establishing proof of concept. To help speed lead optimization earlier in the discovery phase and streamline the surest path to clinic, the team offers extensive capabilities in molecular and cellular pharmacology, including more than 800 assays, multiple assay methodologies, high throughput screening with robotic automation, and expert assay development. To view the extensive catalog of discovery assays, visit the MDS Pharma Services' Pharmacology/DMPK Web site at http://discovery.mdsps.com/Catalog/.

For more information, visit our website at www.mdsps.com.


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Compendia Bioscience Releases Oncomine Concepts Edition 4.0
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
4. Coalition of Business, Labor, Academia and Bioscience Groups to Promote Medical Innovation, Spark Economic Growth
5. Business, Labor, Academia and Bioscience Groups to Launch New Coalition to Promote Medical Innovation and Spark Economic Growth
6. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
7. Pressure BioSciences, Inc. Provides Corporate Update
8. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
9. Cell Biosciences Announces First UK System Sale
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
11. PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Hospital-Grade Disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... , ... The John P. McGovern Museum of Health and Medical Science is ... cognitive health, and share results with their physicians. Members and guests can sign up ... , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a new ... a day, Quick Care provides patients with the option to request and begin ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: